Management of the Ocular Surface With Preservative-Free Lubricants in Patients With Dry Eye

Last updated: November 29, 2023
Sponsor: Tecnoquimicas
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sjogren's Syndrome

Dry Eye Disease

Eyelid Inflammation

Treatment

Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)

Clinical Study ID

NCT06162442
CEI-001
  • Ages 18-45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Observational and prospective cohort study that seek to evaluate the epidemiological characteristics and changes in the ocular surface of patients diagnosed with dry eye disease who are treated with preservative-free lubricating drops.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ability to sign informed consent.
  • Any sex.
  • Women of reproductive age should secure a method during the contraceptive study.
  • Diagnosis of dry eye (mild, moderate) prior to the study in treatment with lubricantswith preservatives.

Exclusion

Exclusion Criteria:

  • Patients with any acquired or congenital anomaly or ocular malformation that preventsan adequate exploration of the ocular surface.
  • Patients with a history of ocular surface surgery (cornea and conjunctiva).
  • Patients being treated with medications that may compromise the state of the ocularsurface: glaucoma, allergy, scarring diseases.
  • Patients with allergy to fluorescein, lissamine green or tetracaine.
  • Patients with lacrimal duct obstruction
  • Severe dry eye
  • Kidney failure
  • Liver failure
  • Pregnancy
  • Breastfeeding

Study Design

Total Participants: 132
Treatment Group(s): 1
Primary Treatment: Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)
Phase:
Study Start date:
March 15, 2023
Estimated Completion Date:
April 15, 2024

Study Description

Question Research: What are the clinical and epidemiological characteristics of patients with dry eye treated with preservative-free lubricating drops at Clínica Sigma? JUSTIFICATION The true importance of dry eye lies in the great impact that it is having today throughout the world, both in the visual quality and in the life of those who suffer from it. Preservative-free lubricating drops are part of the treatment to alleviate the symptoms of DED and their management is becoming more frequent and improves for the patient due to the fewer reports of adverse events in their use. Currently, in Colombia there is little scientific evidence. In particular, at the regional level, there is no characterization of DED, which allows determining its causes for a timely diagnosis and adequate treatment of the patient. From the Sigma Clinic, knowing the epidemiological characterization of the population that consults for symptoms of mild to moderate dry eye, will allow establishing risk factors and evaluating the evolution of the disease with clinical staining tests and knowing the visual quality of the patient with the use of questionnaires. GENERAL OBJECTIVE: To describe the clinical and epidemiological characteristics of patients with mild to moderate dry eye treated with preservative-free lubricating drops at the Sigma Clinic. SPECIFIC OBJECTIVES: 1.Evaluate through OSDI and DEQ questionnaires the clinical evolution of patients diagnosed with mild to moderate dry eye treated with preservative-free lubricants from Clínica Sigma. 2. Assess the frequency and severity of symptoms with the SANDE questionnaire in patients with moderate to dry eye treated with preservative-free lubricants from Clínica Sigma. 3. Assess the quality of life with the NEI VFQ-25 questionnaire in patients with moderate to dry eye treated with preservative-free lubricants from Clínica Sigma.Prospective cohort study in patients with a previous diagnosis of mild dry eye and moderate dry eye, classified by DEWS II scale.

Those who wish to participate in the study will be informed at the first ophthalmological care of the need to withdraw the medication they were using for the usual treatment and start a wash-out for seven days. After seven days, the patient will start with the Glicolub Ultra® lubricant with a dosage of 1 drop every 6 hours in both eyes and the following three visits will be made by the study ophthalmologist in their 1st week, 3rd month and 6omes, with Glicolub Ultra® preservative-free lubricating drops. The information obtained will be recorded in the case report formats, initial CRF-1 and follow-up CRF-2, designed for this study and within the clinical history of the participating subject. During each of these services, the participating subjects will fill out the five self-assessment questionnaires, on the OSDI, SANDE, DEQ-5, NEI VFQ-25 scales and a similar tolerability scale (see annexes). The completion will be done online (after training the platform) or by print with an estimated duration of 30 to 40 minutes.

In turn, the participant agrees to return the Glicolub Ultra® vials used during the study to the main investigator. Which, will allow to determine the adherence to the treatment after its weighing and verification of use.

Connect with a study center

  • Clínica Sigma

    Cali, Valle Del Cauca 760044
    Colombia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.